Trial Profile
Cambridge Brain Mets Trial 1: A proof of principle phase 1b / randomised phase 2 study of afatinib penetration into cerebral metastases for patients undergoing neurosurgical resection, both with and without prior low dose, targeted radiotherapy
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Afatinib (Primary) ; Corticosteroids
- Indications Advanced breast cancer; Brain metastases; Lung cancer; Male breast cancer
- Focus Pharmacokinetics; Proof of concept
- Acronyms CamBMT1
- 30 Jan 2024 Status changed from recruiting to discontinued.
- 12 Jan 2021 Planned primary completion date changed from 1 Oct 2020 to 1 Jun 2021.
- 12 Dec 2018 Planned End Date changed from 1 Dec 2019 to 1 Dec 2021.